CCO Expert Recap

Myelodysplastic Syndromes

Source: CCO Independent Conference Coverage of the American Society of Hematology 2007 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Myelodysplastic Syndromes

CME Program Director: Roy A. Beveridge, MD

Faculty:

Alan F. List, MD

CME CREDIT INFORMATION

Release Date: 02/21/08

Expiration Date: 02/20/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 0.9 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the results of recent studies of the use of methyltransferase inhibitors in myelodysplastic syndromes
Discuss the development of new agents for use in the management of patients with myelodysplastic syndromes
Summarize new developments in the analysis of cytogenetic characteristics and the treatment of myelodysplastic syndromes
Relate outcomes of the analysis of supportive care in treatment of patients with myelodysplastic syndromes

CCO Expert Recaps combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.